IL261354A - Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereof - Google Patents
Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereofInfo
- Publication number
- IL261354A IL261354A IL261354A IL26135418A IL261354A IL 261354 A IL261354 A IL 261354A IL 261354 A IL261354 A IL 261354A IL 26135418 A IL26135418 A IL 26135418A IL 261354 A IL261354 A IL 261354A
- Authority
- IL
- Israel
- Prior art keywords
- phenylnucleotides
- hla
- genes
- cancer cells
- leukocyte antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/00112—Receptors for interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299674P | 2016-02-25 | 2016-02-25 | |
| US201662425027P | 2016-11-21 | 2016-11-21 | |
| PCT/US2017/019757 WO2017147600A1 (en) | 2016-02-25 | 2017-02-27 | Whole-cell cancer vaccines and methods for selection thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL261354A true IL261354A (en) | 2018-10-31 |
Family
ID=59685619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261354A IL261354A (en) | 2016-02-25 | 2018-08-23 | Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11559574B2 (https=) |
| EP (1) | EP3419657A4 (https=) |
| JP (1) | JP6901505B2 (https=) |
| CN (1) | CN109069603A (https=) |
| AU (3) | AU2017224232B2 (https=) |
| CA (2) | CA3015080A1 (https=) |
| IL (1) | IL261354A (https=) |
| NZ (1) | NZ745327A (https=) |
| WO (1) | WO2017147600A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3419657A4 (en) | 2016-02-25 | 2019-11-06 | Briacell Therapeutics Corp. | CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF |
| AU2018378201A1 (en) * | 2017-12-04 | 2020-05-21 | Heat Biologics, Inc. | Production of cell-based vaccines |
| EP3727467A4 (en) * | 2017-12-22 | 2021-12-01 | Centivax, Inc. | MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE |
| CN108175853A (zh) * | 2018-01-24 | 2018-06-19 | 上海赛群生物科技有限公司 | 一种肿瘤细胞疫苗及其制备方法 |
| CN108486038B (zh) * | 2018-03-21 | 2021-08-27 | 中国人民解放军第四军医大学 | 一种构建脂肪干细胞膜片的方法及应用 |
| EP4582440A3 (en) * | 2018-12-21 | 2025-10-08 | The Regents of the University of California | Il-10-containing vaccines and uses thereof |
| AU2020395765A1 (en) | 2019-12-03 | 2022-06-16 | Neuvogen, Inc. | Tumor cell vaccines |
| CN110938630B (zh) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | 人b3gnt5基因的用途及相关产品 |
| US20250020652A1 (en) * | 2021-11-18 | 2025-01-16 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based cancer treatments |
| IL315361A (en) | 2022-03-03 | 2024-11-01 | Briacell Therapeutics Corp | Cancer vaccines and methods of use thereof |
| CN115433734B (zh) * | 2022-06-01 | 2025-03-04 | 北京奇糖科技有限公司 | 核酸片段及其在制备肿瘤疫苗中的应用 |
| CN117990593A (zh) * | 2024-01-31 | 2024-05-07 | 南昌铭硕生科生物工程有限公司 | 一种流式多因子分析系统及其分析方法 |
| WO2025171109A1 (en) | 2024-02-07 | 2025-08-14 | Briacell Therapeutics Corp. | Cancer vaccines expressing post-translational modified antigens and methods of use thereof |
| CN118207320A (zh) * | 2024-04-28 | 2024-06-18 | 复旦大学附属中山医院 | Hla-c*04:01基因的新用途及检测试剂盒 |
| CN118207319A (zh) * | 2024-04-28 | 2024-06-18 | 复旦大学附属中山医院 | Hla-a*03:04基因的新用途及检测试剂盒 |
| WO2026068517A1 (en) * | 2024-09-24 | 2026-04-02 | Universiteit Gent | Cancer immunotherapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
| US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
| JP2002536996A (ja) * | 1999-02-22 | 2002-11-05 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | チロシンキナーゼ受容体ＥｐｈＡ３抗原ペプチド |
| US7674456B2 (en) | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| WO2006081629A1 (en) | 2005-02-04 | 2006-08-10 | Stem Cell Australia Pty Ltd | Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy. |
| WO2006135454A1 (en) * | 2005-06-08 | 2006-12-21 | Saint Vincent Medical Center, A California Corporation | Novel cancer cell lines and uses thereof |
| US20080020386A1 (en) | 2006-03-29 | 2008-01-24 | Medigen Biotechnology Corporation | Methods and apparatus for genotyping |
| US7807186B2 (en) * | 2007-01-17 | 2010-10-05 | University Of Maryland, Baltimore County | Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines |
| WO2010045573A2 (en) | 2008-10-17 | 2010-04-22 | University Of Miami | Tumor vaccine |
| AU2012257377B2 (en) | 2011-05-17 | 2017-09-07 | Hadasit Medical Research Services And Development Ltd. | Allogeneic tumor cell vaccination |
| EP3419657A4 (en) | 2016-02-25 | 2019-11-06 | Briacell Therapeutics Corp. | CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF |
-
2017
- 2017-02-27 EP EP17757429.0A patent/EP3419657A4/en active Pending
- 2017-02-27 CN CN201780023982.8A patent/CN109069603A/zh active Pending
- 2017-02-27 WO PCT/US2017/019757 patent/WO2017147600A1/en not_active Ceased
- 2017-02-27 CA CA3015080A patent/CA3015080A1/en active Pending
- 2017-02-27 AU AU2017224232A patent/AU2017224232B2/en active Active
- 2017-02-27 NZ NZ745327A patent/NZ745327A/en unknown
- 2017-02-27 JP JP2018563769A patent/JP6901505B2/ja active Active
- 2017-02-27 CA CA3300406A patent/CA3300406A1/en active Pending
-
2018
- 2018-08-23 US US16/110,317 patent/US11559574B2/en active Active
- 2018-08-23 IL IL261354A patent/IL261354A/en unknown
-
2022
- 2022-10-28 AU AU2022259857A patent/AU2022259857B2/en active Active
- 2022-12-09 US US18/078,351 patent/US20230277640A1/en active Pending
-
2025
- 2025-07-03 AU AU2025205094A patent/AU2025205094A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230277640A1 (en) | 2023-09-07 |
| NZ785587A (en) | 2025-02-28 |
| AU2017224232A1 (en) | 2018-09-06 |
| EP3419657A4 (en) | 2019-11-06 |
| JP6901505B2 (ja) | 2021-07-14 |
| CA3015080A1 (en) | 2017-08-31 |
| US20190046624A1 (en) | 2019-02-14 |
| NZ745327A (en) | 2023-06-30 |
| WO2017147600A1 (en) | 2017-08-31 |
| CA3300406A1 (en) | 2026-03-02 |
| AU2025205094A1 (en) | 2025-07-24 |
| US11559574B2 (en) | 2023-01-24 |
| EP3419657A1 (en) | 2019-01-02 |
| CN109069603A (zh) | 2018-12-21 |
| AU2022259857B2 (en) | 2025-05-29 |
| JP2019507608A (ja) | 2019-03-22 |
| AU2017224232B2 (en) | 2022-07-28 |
| AU2022259857A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261354A (en) | Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereof | |
| IL288784A (en) | Anti-garp antibodies, nucleotides encoding same, vectors, cells and compositions comparising same, methods of producing same and uses thereof | |
| CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| IL269440B (en) | Closed systems for use in selecting immune cell populations for adoptive therapy | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| HUE053366T2 (hu) | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk | |
| IL261963A (en) | Antibodies, pharmaceutical compositions and methods | |
| IL263846B (en) | Formulation of a peptide vaccine | |
| HUE045993T2 (hu) | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások | |
| IL257563A (en) | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin | |
| IL268704B (en) | Formulations of human anti-rankl antibodies, and methods of using the same | |
| HUE056677T2 (hu) | Anti-tim-3 ellenanyagok és készítmények | |
| IL255631B (en) | Compositions and methods for screening t cells with antigens for specific populations | |
| IL256652A (en) | Therapeutic compositions, combinations, and methods of use | |
| IL254214A0 (en) | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer | |
| DK3707261T3 (da) | Fusionsproteiner baseret på humant ferritin og protease-spaltbare peptider og deres anvendelse som kemoterapi-bærestoffer | |
| HUE066356T2 (hu) | GLP-1 készítmények és alkalmazásaik | |
| IL263629B (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| IL244149A0 (en) | Methods and compositions comprising purified recombinant polypeptides | |
| MX392779B (es) | Anticuerpos anti-cd27 | |
| MY191944A (en) | Binding proteins and methods of use thereof | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| MA49874A (fr) | Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant | |
| MX382518B (es) | Antigenos de citomegalovirus y su uso. |